文献速递神经肌肉病

肌萎缩侧索硬化症相关新基因:诊断与临床意义

Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications.
PubMed 文献 · Lancet Neurol · 2017-11-16

本文综述了2014年以来通过全基因组关联研究、全基因组研究或外显子组测序技术新发现的7个与肌萎缩侧索硬化症(ALS)相关的基因(MATR3、CHCHD10、TBK1、TUBA4A、NEK1、C21orf2和CCNF),这些基因编码的蛋白质涉及蛋白质稳态、线粒体功能、RNA代谢、细胞骨架完整性、轴突运输和DNA修复等通路。这些发现有助于揭示ALS的分子机制并识别潜在治疗靶点,但新基因的效应尚未在动物模型中研究,且基因检测成为常规诊断的一部分后才能直接影响临床实践。

要点

  • 2014年以来新发现7个ALS相关基因,均通过基因组学技术鉴定。
  • 新基因涉及蛋白质稳态、线粒体功能、RNA代谢等共同疾病通路。
  • 针对这些通路的治疗可能适用于按基因型分层的广泛患者群体。

核心结论

  • 新发现的7个ALS相关基因有助于阐明ALS的分子机制并识别潜在治疗靶点,但尚需动物模型研究验证。

研究设计与样本

  • 本文为综述,汇总了2014年以来通过全基因组关联研究、全基因组研究或外显子组测序技术发现的ALS相关基因。

主要发现

  • 自2014年以来,7个新基因(MATR3、CHCHD10、TBK1、TUBA4A、NEK1、C21orf2和CCNF)被证实与ALS相关。
  • 每个新基因编码的蛋白质均涉及一个或多个已知ALS相关分子通路,包括蛋白质聚集或清除缺陷导致的蛋白质稳态失调、线粒体功能障碍、RNA代谢改变、细胞骨架完整性受损、轴突运输动力学改变以及DNA修复缺陷导致的DNA损伤积累。
  • 这些新基因与其他ALS相关基因共享共同疾病通路,因此靶向这些通路的治疗可能对按基因型分层的广泛患者群体有用。
  • 这些新基因的效应尚未在动物模型中进行研究。

临床怎么用

  • 当基因组测序成为疾病诊断和管理的常规组成部分时,这些遗传学发现将直接影响临床实践。
  • 针对共同疾病通路的治疗可能适用于按基因型分层的广泛ALS患者群体。

局限性

  • 对ALS病因的理解尚不完整,需要进一步遗传学研究提供更多细节。
  • 新基因的效应尚未在动物模型中研究,这是将发现转化为临床实践的关键步骤。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The disease course of amyotrophic lateral sclerosis (ALS) is rapid and, because its pathophysiology is unclear, few effective treatments are available. Genetic research aims to understand the underlying mechanisms of ALS and identify potential therapeutic targets. The first gene associated with ALS was SOD1, identified in 1993 and, by early 2014, more than 20 genes had been identified as causative of, or highly associated with, ALS. These genetic discoveries have identified key disease pathways that are therapeutically testable and could potentially lead to the development of better treatments for people with ALS. RECENT DEVELOPMENTS: Since 2014, seven additional genes have been associated with ALS (MATR3, CHCHD10, TBK1, TUBA4A, NEK1, C21orf2, and CCNF), all of which were identified by genome-wide association studies, whole genome studies, or exome sequencing technologies. Each of the seven novel genes code for proteins associated with one or more molecular pathways known to be involved in ALS. These pathways include dysfunction in global protein homoeostasis resulting from abnormal protein aggregation or a defect in the protein clearance pathway, mitochondrial dysfunction, altered RNA metabolism, impaired cytoskeletal integrity, altered axonal transport dynamics, and DNA damage accumulation due to defective DNA repair. Because these novel genes share common disease pathways with other genes implicated in ALS, therapeutics targeting these pathways could be useful for a broad group of patients stratified by genotype. However, the effects of these novel genes have not yet been investigated in animal models, which will be a key step to translating these findings into clinical practice. WHERE NEXT?: The identification of these seven novel genes has been important in unravelling the molecular mechanisms underlying ALS. However, our understanding of what causes ALS is not complete, and further genetic research will provide additional detail about its causes. Increased genetic knowledge will also identify potential therapeutic targets and could lead to the development of individualised medicine for patients with ALS. These developments will have a direct effect on clinical practice when genome sequencing becomes a routine and integral part of disease diagnosis and management.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Chia R, Chiò A, Traynor BJ, et al. Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol. 2017. PMID: 29154141. doi:10.1016/S1474-4422(17)30401-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。